IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial

Reuters01-12

IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial

IN8bio, Inc. has announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials evaluating DeltEx Drug-Resistant Immunotherapy $(DRI)$ gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM). The results were presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The data showed that repeat-doses of DeltEx DRI γδ T cells nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in a standard-of-care $(SOC)$ control cohort. Median overall survival (mOS) was reported at 17.2+ months as of December 31, 2025, compared to 13.2 months for SOC. The treatment demonstrated a favorable safety profile, with no treatment-related severe adverse events or dose limiting toxicities observed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623484-en) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602510848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602510848","market":"us","top_or_hot":-1,"title":"IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INAB\">IN8bio, Inc.</a> has announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials evaluating DeltEx Drug-Resistant Immunotherapy <a href=\"https://laohu8.com/S/DRI\">$(DRI)$</a> gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM). The results were presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The data showed that repeat-doses of DeltEx DRI γδ T cells nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in a standard-of-care <a href=\"https://laohu8.com/S/SOC\">$(SOC)$</a> control cohort. Median overall survival (mOS) was reported at 17.2+ months as of December 31, 2025, compared to 13.2 months for SOC. The treatment demonstrated a favorable safety profile, with no treatment-related severe adverse events or dose limiting toxicities observed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623484-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/INAB\">IN8bio, Inc.</a> has announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials evaluating DeltEx Drug-Resistant Immunotherapy <a href=\"https://laohu8.com/S/DRI\">$(DRI)$</a> gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM). The results were presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The data showed that repeat-doses of DeltEx DRI γδ T cells nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in a standard-of-care <a href=\"https://laohu8.com/S/SOC\">$(SOC)$</a> control cohort. Median overall survival (mOS) was reported at 17.2+ months as of December 31, 2025, compared to 13.2 months for SOC. The treatment demonstrated a favorable safety profile, with no treatment-related severe adverse events or dose limiting toxicities observed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623484-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6bfg4T:1","article_id":"2602510848","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602510848","pubTimestamp":1768222878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8bio, Inc. has announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials evaluating DeltEx Drug-Resistant Immunotherapy  gamma-delta (γδ) T cells in newly diagnosed glioblastoma . The results were presented at the 2025 Society for Neuro-Oncology  Annual Meeting. The data showed that repeat-doses of DeltEx DRI γδ T cells nearly doubled median progression-free survival  to 13.0 months compared to 6.6 months in a standard-of-care  control cohort. Median overall survival  was reported at 17.2+ months as of December 31, 2025, compared to 13.2 months for SOC. The treatment demonstrated a favorable safety profile, with no treatment-related severe adverse events or dose limiting toxicities observed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4539":"次新股","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","INAB":"IN8bio, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"IN8Bio γ-δ T细胞疗法在胶质母细胞瘤试验中使无进展生存期几乎翻了一番","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9,"NDAQ":0.9},"content_text":"IN8bio Gamma-Delta T Cell Therapy Nearly Doubles Progression-Free Survival in Glioblastoma Trial\n    \n\nIN8bio, Inc. has announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials evaluating DeltEx Drug-Resistant Immunotherapy $(DRI)$ gamma-delta (γδ) T cells in newly diagnosed glioblastoma (GBM). The results were presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The data showed that repeat-doses of DeltEx DRI γδ T cells nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in a standard-of-care $(SOC)$ control cohort. Median overall survival (mOS) was reported at 17.2+ months as of December 31, 2025, compared to 13.2 months for SOC. The treatment demonstrated a favorable safety profile, with no treatment-related severe adverse events or dose limiting toxicities observed.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623484-en) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602510848","isCrawlerRequest":true}